SYGNIS Announces Last Patient Treated in its AXIS 2 Efficacy Study
Complete the form below to unlock access to ALL audio articles.
SYGNIS Pharma AG has announced the completion of the treatment for its randomized, double-blind study designed to demonstrate the efficacy of AX200 for the treatment of patients with acute ischemic stroke (AXIS 2). 328 patients have been treated across eight European countries.
AX200 has a dual mechanism-of-action in the treatment of acute stroke, stopping neuronal cell death and promoting the regeneration of the damaged CNS tissue, providing a new, first-in-class approach to treating stroke patients.
Dr. Frank Rathgeb, Chief Medical Officer of SYGNIS, commented: “We are pleased to have completed treatment in our clinical phase II efficacy study and are now finalizing the data collection. We expect to report initial findings of the AXIS 2 Study towards the end of 2011”.
Going forward, SYGNIS will review the options for the development and marketing of AX200.
Possibilities include continuing development by the company itself or through out licensing to external parties. In addition, SYGNIS will consider developing AX200 together with a partner.
